An evaluation of a multi-site community pharmacy-based chronic obstructive pulmonary disease support service

International Journal of Pharmacy Practice

Volumn 23, Issue 1, 2015, Pages 36-43

  Wright, David ^a   Twigg, Michael ^a   Barton, Garry ^b   Thornley, Tracey ^c   Kerr, Clare ^d  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c The Boots Company PLC   (United Kingdom)

^d Celesio UK   (United Kingdom)

Author keywords

adherence; chronic obstructive pulmonary disease; community pharmacy; economic evaluation; quality of life

Indexed keywords

ANTIBIOTIC AGENT; STEROID;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FEMALE; GENERAL PRACTITIONER; HEALTH CARE ACCESS; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NATIONAL HEALTH SERVICE; OUTCOME ASSESSMENT; PHARMACIST; PHARMACY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; SMOKING CESSATION; UNITED KINGDOM; AGED; ECONOMICS; EVALUATION STUDY; HEALTH CARE COST; PATIENT ATTITUDE; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA; UTILIZATION;

AGED; COMMUNITY PHARMACY SERVICES; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MEDICATION ADHERENCE; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT ACCEPTANCE OF HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE;

EID: 84922478837     PISSN: 09617671     EISSN: 20427174     Source Type: Journal    
DOI: 10.1111/ijpp.12165     Document Type: Article

References (37)

1. Global Initiative for Chronic Obstructive Lung Disease (2010). Global Strategy for the Diagnosis, Management, and Prevention of COPD: Updated 2010. http://www.goldcopd.org/uploads/users/files/GOLDReport-April112011.pdf (accessed 11 November 2014).
2. WHO (2008). World Health Statistics 2008. http://www.who.int/whosis/whostat/EN-WHS08-Full.pdf (accessed 20 October 2013).
3. Sin DD, etal. Mortality in COPD: role of comorbidities. European Respiratory Journal 2006; 28: 1245-1257.
4. Buist AS, etal. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741-750.
5. Anon,. Appendix D: economics costs of COPD to the NHS. Thorax 2004; 59 (Suppl): i192-i194.
6. Decramer M, etal. Chronic obstructive pulmonary disease. Lancet 2012; 379: 1341-1351.
7. NICE ed. Chronic obstructive pulmonary disease (CG101). In: National Institute for Health and Care Excellence. London: The Stationery Office, 2010.
8. Bryant L, etal. Adequacy of inhaler technique used by people with asthma or chronic obstructive pulmonary disease. J Prim Health Care 2013; 5: 191-198.
9. Lareau SC, Yawn B,. Improving adherence with inhaler therapy in COPD. Int J Chron Obstruct Pulmon Dis 2010; 5: 401-406.
10. Tovar JM, Gums J,. Monitoring pulmonary function in asthma and COPD: point-of-care testing. Ann Pharmacother 2004; 38: 126-133.
11. Margolis A, etal. A telepharmacy intervention to improve inhaler adherence in veterans with chronic obstructive pulmonary disease. Am J Health Syst Pharm 2013; 70: 1875-1876.
12. NHS Improving Quality. Managing COPD as a Long-Term Condition: Emerging Learning from the National Improvement Projects. http://improvementsystem.nhsiq.nhs.uk/ImprovementSystem/ViewDocument.aspx?path=Cancer%2FNational%2FNational%20Project%2FLung%20Publication%2FLungChronicManagement.pdf (accessed 11 November 2014).
13. Jones PW, etal. Development and first validation of the COPD assessment test. Eur Respir J 2009; 11: 648-654.
14. Wouters E,. The societal impact of COPD in North America and Europe: an economic analysis of the confronting COPD survey. Respir Med 2003; 97 (Suppl. C): S3-S14.
15. Mehuys E, etal. COPD management in primary care: an observational community pharmacy-based study. Annals of Pharmacotherapy 2010; 44: 257-266.
16. Beauchesne M, etal. Community pharmacy-based medication assessment program for asthma and chronic obstructive pulmonary disease. Can Pharm J 2012; 145: 70-71.
17. Ottenbros S, etal. Pharmacist-led intervention study to improve drug therapy in asthma and COPD patients. International journal of clinical pharmacy 2014; 36: 336-344.
18. Tommelein E, etal. Effectiveness of pharmaceutical care for patients with chronic obstructive pulmonary disease (PHARMACOP): a randomized controlled trial. Br J Clin Pharmacol 2014; 77: 756-766.
19. Pharmacy Services Negotiating Committee. People with asthma benefit from medication reviews delivered by pharmacists [press release]. 2012.
20. Team N. Data show that the new medicine service is helping patients take their medicines properly. 2012.
21. Khdour MR, etal. Cost-utility analysis of a pharmacy-led self-management programme for patients with COPD. Int J Clin Pharm 2011; 33: 665-673.
22. Fletcher CM, etal. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959; 2: 257-266.
23. Herdman M, etal. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011; 20: 1727-1736.
24. Morisky DE, etal. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens 2008; 10: 348-354.
25. NICE. Guide to the methods of technology appraisal 2013. National Institute of Health and Clinical Excellence (NICE) publications: 2013.
26. Manca A, etal. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005; 14: 487-496.
27. Fenwick E, etal. Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions. Health Econ 2004; 13: 405-415.
28. Gray A, etal. Applied Methods of Cost-Effectiveness Analysis in Healthcare. Oxford: Oxford University Press, 2011.
29. Benzo R, etal. Development and feasibility of a self-management intervention for chronic obstructive pulmonary disease delivered with motivational interviewing strategies. Journal of cardiopulmonary rehabilitation and prevention 2013; 33: 113-123.
30. Sohanpal R, etal. Reporting participation rates in studies of non-pharmacological interventions for patients with chronic obstructive pulmonary disease: a systematic review. Systematic reviews 2012; 1: 66.
31. Mehuys E, etal. Effectiveness of a community pharmacist intervention in diabetes care: a randomized controlled trial. J Clin Pharm Ther 2011; 36: 602-613.
32. McLean DL, etal. A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN). Arch Intern Med 2008; 168: 2355-2361.
33. Department of Health (2013). Seasonal Flu Vaccine Uptake in GP Patients 2012-2013: Provisional Data for 1 September 2012 to 31 January 2013. https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/203238/SeasonalFluData-GPs-Jan13-acc.pdf (accessed 6 September 2013).
34. Curtis L., Unit costs of health and social care. The University of Kent, 2013.
35. Department of Health. Reference Costs 2011-2012. Department of Health: 2012.
36. Schomberg LEE, Garner JL, Porter JW, Bahadur K, Ross L, Kosky CA, etal. Does the provision of a rescue pack keep patients with chronic obstructive pulmonary disease (COPD) at home? Thorax. 2011; 66: A174.
37. Office for National Statistics. Annual Survey of Hours and Earnings, 2011 Revised Results (SOC 2010). Available at http://www.ons.gov.uk/ons/rel/ashe/annual-survey-of-hours-and-earnings/2011-revised-results-soc-2010-/index.html (accessed 4 November 2013: 2011).